Your browser doesn't support javascript.
loading
Carnitine in Alleviation of Complications Caused by Acute Valproic Acid Toxicity; an Exprimental Study on Mice.
Jamshidzadeh, Akram; Heidari, Reza; Shams, Mahdie; Ebrahimi-Sharghi, Melika; Marashi, Sayed Mahdi.
Afiliación
  • Jamshidzadeh A; Department of Pharmacology Toxicology, School of Pharmacy, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Heidari R; Department of Pharmacology Toxicology, School of Pharmacy, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Shams M; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Ebrahimi-Sharghi M; Student Research Committee of Pharmacy School, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Marashi SM; Department of Forensic Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Arch Acad Emerg Med ; 12(1): e20, 2024.
Article en En | MEDLINE | ID: mdl-38371450
ABSTRACT

Introduction:

Hyperammonemia and hepatotoxicity are well-known complications of valproic acid (VPA) poisoning. The objective of this study is to evaluate the potential role of carnitine in mitigating the adverse effects of acute VPA toxicity in mice.

Methods:

54 male mice (25-30 g) were randomly assigned to one of three categories, including acute, sub-acute, and chronic poisoning. Each category contained 3 groups, each consisting of 6 mice (Group 1 control, Group 2 VPA treated, and Group 3 VPA + carnitine treated). The animals were sacrificed 24 hours after the initial injection, and their blood, liver, and brain samples were compared between groups of each category regarding liver function biomarkers, oxidative stress markers, ammonia level, and liver histopathologic changes using one-way ANOVA followed by Tukey's multiple comparison test.

Results:

The administration of VPA increased the serum level of aspartate aminotransferase (AST) (p=0.003) and alanine aminotransferase (ALT) (p=0.001), as well as serum, and brain level of ammonia (p=0.0001 for both) in the intervention group. Elevated levels of lipid peroxidation and oxidative stress (p=0.0001 for both) in the liver tissue, decreased liver glutathione (p=0.0001) and ferric ion-reducing antioxidant power (FRAP) (p=0.0001), and histopathologic changes in the form of moderate to severe inflammation were observed. Administration of VPA + carnitine reduced AST (p=0.05) and ALT (p=0.01), increased the FRAP, reduced free oxygen radicals and liver lipid peroxidation (p=0.0001 for all), and decreased tissue damage in the form of moderate inflammation. The administration of carnitine was ineffective in reducing brain or plasma ammonia levels in acute VPA-treated animals (p = 0.0115).

Conclusions:

Although the administration of carnitine has been suggested as a protective remedy in cases of VPA toxicity, according to the present study, it did not have an antidotal effect and did not prevent encephalopathy or liver injury in acute VPA toxicity.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Arch Acad Emerg Med Año: 2024 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Arch Acad Emerg Med Año: 2024 Tipo del documento: Article País de afiliación: Irán